Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma

The National Comprehensive Cancer Network

William T. McGivney · Cancer · 1998 · 16.9K citations

Medicine, Oncology, Clinical Informatics +15

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0

Ronald Boellaard, Roberto C. Delgado Bolton, Wim J.G. Oyen et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2014 · 3.3K citations · Full text

Medicine, Nuclear Medicine, Radiology +17

Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer

Shamima Rahman, S. E. Olpin · Nature Genetics · 2002 · 1.6K citations

Medicine, Genetics, Molecular Genetics +16

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov et al. · The Lancet Oncology · 2018 · 368 citations

Medicine, Oncology, Pharmacology +10

Aberrant succination of proteins in fumarate hydratase‐deficient mice and HLRCC patients is a robust biomarker of mutation status

Chiara Bardella, Mona El‐Bahrawy, Norma Frizzell et al. · The Journal of Pathology · 2011 · 279 citations

Medicine, Biochemistry, Oncology +17